Pegcetacoplan interacts in the following cases:
There are no data available for the use of pegcetacoplan in patients with end-stage renal disease (ESRD) requiring haemodialysis.
There may be interference between silica reagents in coagulation panels and pegcetacoplan that results in artificially prolonged activated partial thromboplastin time (aPTT); therefore, the use of silica reagents in coagulation panels should be avoided.
There are no or limited amount of data from the use of pegcetacoplan in pregnant women. Studies in animals have shown reproductive toxicity.
Pegcetacoplan is not recommended during pregnancy and in women of childbearing potential not using contraception.
It is unknown whether pegcetacoplan is excreted in human milk. The potential for absorption and harm to the breastfed infant is unknown. Animal data suggest a low excretion (less than 1%, not pharmacologically significant) of pegcetacoplan in monkey milk. It is unlikely that a breastfed infant would have clinically relevant exposure.
It is recommended to discontinue breast-feeding during pegcetacoplan treatment.
It is recommended that women of childbearing potential use effective contraception methods to prevent pregnancy during treatment with pegcetacoplan and for at least 8 weeks after the last dose of pegcetacoplan. For women planning to become pregnant, the use of pegcetacoplan may be considered following an assessment of the risks and benefits.
No animal or human data on the effect of pegcetacoplan on fertility are available. In toxicity studies, there were no microscopic abnormalities in male or female reproductive organs in monkeys.
Pegcetacoplan has no or negligible influence on the ability to drive and use machines.
The most commonly reported adverse reactions in patients with PNH treated with pegcetacoplan were injection site reactions: injection site erythema, injection site pruritus, injection site swelling, injection site pain, injection site bruising. Other adverse reactions reported in more than 10% of patients during clinical studies were upper respiratory tract infection, diarrhoea, haemolysis, abdominal pain, headache, fatigue, pyrexia, cough, urinary tract infection, vaccination complication, pain in extremity, dizziness, arthralgia and back pain. The most commonly reported serious adverse reactions were haemolysis and sepsis.
The most commonly reported adverse drug reactions in patients with C3G or primary IC-MPGN treated with pegcetacoplan were infusion site reactions and upper respiratory tract infections. The most commonly reported serious adverse reactions were acute kidney injury and pneumonia.
The table below gives the adverse reactions observed from the clinical studies and postmarketing experience with pegcetacoplan in patients with PNH, C3G and primary IC-MPGN. Adverse reactions are listed by MedDRA system organ class (SOC) and frequency, using the following convention: very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1 000 to <1/100) or rare (≥1/10 000 to <1/1 000), very rare (<1/10 000), and not known (cannot be estimated from available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Adverse reactions from clinical trials 1 and postmarketing experience:
| MedDRA System Organ Class Adverse reaction | Frequency in PNH | Frequency in C3G or primary IC-MPGN |
| Infections and infestations | ||
| Influenza | Very common | |
| Upper respiratory tract infections2 | Very common | Very common |
| Urinary tract infection | Very common | Common |
| Sepsis | Common3 | |
| Opportunistic infections | Common4 | |
| COVID-19, Gastrointestinal infection, Fungal infection, Skin infection, Oral infection | Common | |
| Ear infection | Common | Common |
| Infection, Respiratory tract infection5, Viral infection, Bacterial infection, Vaginal infection, Eye infection | Common | |
| Cervicitis, Groin infection | Uncommon | |
| Pneumonia | Uncommon | Common |
| Nasal abscess, Tuberculosis, Oesophageal candidiasis, COVID-19 pneumonia, Anal abscess | Uncommon | |
| Immune system disorders | ||
| Hypersensitivity reaction | Very common6 | |
| Blood and lymphatic system disorders | ||
| Haemolysis | Very common | |
| Thrombocytopenia | Common | Common7 |
| Neutropenia | Common | Common |
| Metabolism and nutrition disorders | ||
| Hypokalaemia | Common | Common |
| Nervous system disorders | ||
| Headache | Very common | Very common |
| Dizziness | Very common | |
| Vascular disorders | ||
| Hypertension | Common | |
| Respiratory, thoracic and mediastinal disorders | ||
| Cough | Very common | Common |
| Dyspnoea, Oropharyngeal pain, Nasal congestion | Common | |
| Epistaxis | Common | Common |
| Gastrointestinal disorders | ||
| Abdominal pain | Very common | |
| Diarrhoea | Very common | Very common |
| Nausea | Common | Very common |
| Skin and subcutaneous tissue disorders | ||
| Erythema, Rash, Urticaria | Common | |
| Musculoskeletal and connective tissue disorders | ||
| Arthralgia, Back pain | Very common | |
| Pain in extremity | Very common | Common |
| Myalgia | Common | Common |
| Muscle spasms | Common | |
| Renal and urinary disorders | ||
| Acute kidney injury | Common | Very common |
| Chromaturia | Common | |
| General disorders and administration site conditions | ||
| Pyrexia | Very common | Very common |
| Fatigue | Very common | Common |
| Infusion site reactions8 | Very common | Very common |
| Investigations | ||
| Alanine aminotransferase increased, Bilirubin increased | Common | |
| Injury, poisoning and procedural complications | ||
| Vaccination complication | Very common | |
1 Studies APL2-308, APL2-302, APL2-202, APL2-CP-PNH-204, and APL-CP0514 in PNH patients and Study APL2-C3G-310, APL2-C3G-314, APL2-201 and APL2-C3G-204 in C3G and primary IC-MPGN patients. Medically similar terms are grouped, where appropriate, on the basis of similar medical concept.
2 Include nasopharyngitis, upper respiratory tract infection, pharyngitis, rhinitis and sinusitis.
3 Sepsis includes one case of septic shock and one case with non-encapsulated Neisseria meningitidis.
4 Herpes zoster (including Herpes zoster meningoencephalitis), and Pneumocystis jirovecii infection.
5 Include respiratory tract infection and respiratory tract infection viral.
6 Include rash and eczema.
7 Includes platelet count decreased.
8 PTs included in Infusion site reactions: infusion site erythema, infusion site pruritus, infusion site swelling, infusion site bruising, infusion site pain, infusion site induration.
No serious infection caused by encapsulated bacteria was reported during PNH Study APL2-302. Forty-eight patients experienced an infection during the study. The most frequent infections in patients treated with pegcetacoplan during PNH Study APL2-302 were upper respiratory tract infection (28 cases, 35%). Most infections reported in patients treated with pegcetacoplan during PNH Study APL2-302 were nonserious, and predominantly mild in intensity. Ten patients developed infections reported as serious including one patient who died due to COVID-19. The most frequent serious infections were sepsis (3 cases) (leading to discontinuation of pegcetacoplan in one patient) and gastroenteritis (3 cases); all of which resolved.
In C3G and primary IC-MPGN clinical studies, four serious respiratory tract infections caused by encapsulated bacteria were reported in patients treated with pegcetacoplan: an epiglottitis, a pneumococcal pneumonia and an atypical pneumonia that led to drug interruption, and a pneumonia Haemophilus with no dose adjustment. Events recovered and resolved except for the events of pneumonia Haemophilus and the atypical pneumonia that resolved with sequelae. In addition, one serious Escherichia urinary tract infection was reported, the event recovered and resolved with no dose adjustment.
Nineteen patients reported haemolysis during PNH Study APL2-302 in patients treated with pegcetacoplan. Seven cases were reported as serious, and 5 cases led to discontinuation of pegcetacoplan and the dose of pegcetacoplan was increased in 10 patients. There were 3 cases of haemolysis during PNH Study APL2-308 in patients treated with pegcetacoplan. None of these cases were reported as serious or led to discontinuation of pegcetacoplan. The dose of pegcetacoplan was increased in all 3 patients.
In C3G and primary IC-MPGN clinical studies, 10 serious events of acute kidney injury were reported in 8 patients (5.7%) treated with pegcetacoplan, of which 5 events were observed in 4 post-transplant patients. Of these serious events, only 1 led to drug withdrawal and 1 to dose interruption. All events recovered and resolved, except the single event that led to drug withdrawal.
In the patients with post-transplant recurrent C3G or primary IC-MPGN (N=22), included in Studies APL2-C3G-310 and APL2-C3G-204, the safety profile appeared consistent with that of the overall population, although with higher frequencies of severe and serious adverse events, as expected in this patient population.
In adolescent patients with C3G or primary IC-MPGN (N=28, aged 12 years to 17 years) included in Study APL2-C3G-310, the safety profile appeared consistent with the overall results. The most common adverse reaction reported in this patient population were infusion site reactions. The safety of pegcetacoplan has not been studied in paediatric patients less than 12 years of age.
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.